These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1919633)

  • 1. The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa.
    Urba WJ; Kopp WC; Clark JW; Smith JW; Steis RG; Huber C; Coggin D; Longo DL
    J Clin Oncol; 1991 Oct; 9(10):1831-9. PubMed ID: 1919633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor.
    Schiller JH; Witt PL; Storer B; Alberti D; Tombes MB; Arzoomanian R; Brown RR; Proctor RA; Voss SD; Spriggs DR
    Cancer; 1992 Jan; 69(2):562-71. PubMed ID: 1728387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
    Hofmann B; Bass H; Nishanian P; Faisal M; Figlin RA; Sarna GP; Fahey JL
    Clin Exp Immunol; 1992 Jun; 88(3):548-54. PubMed ID: 1606739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha.
    Aulitzky WE; Aulitzky WK; Frick J; Herold M; Gastl G; Tilg H; Berger M; Huber C
    Immunobiology; 1990 Jun; 180(4-5):385-94. PubMed ID: 2118879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
    Aulitzky WE; Tilg H; Herold M; Berger M; Vogel W; Judmaier G; Gastl G; Mull B; Flener R; Wiegele J
    J Interferon Res; 1988 Oct; 8(5):655-64. PubMed ID: 3148671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
    J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy.
    Hahn G; Stuhlmüller B; Hain N; Kalden JR; Pfizenmaier K; Burmester GR
    J Clin Invest; 1993 Mar; 91(3):862-70. PubMed ID: 8450066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The determination of an immunologically active dose of interferon-gamma in patients with melanoma.
    Maluish AE; Urba WJ; Longo DL; Overton WR; Coggin D; Crisp ER; Williams R; Sherwin SA; Gordon K; Steis RG
    J Clin Oncol; 1988 Mar; 6(3):434-45. PubMed ID: 3127550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant human interleukin-2 and tumor necrosis factor-alpha with or without interferon-gamma on human thyroid tissues from patients with Graves' disease and from normal subjects xenografted into nude mice.
    Kasuga Y; Matsubayashi S; Akasu F; Miller N; Jamieson C; Volpé R
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1296-301. PubMed ID: 1902846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
    Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
    J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.
    Kopp WC; Smith JW; Ewel CH; Alvord WG; Main C; Guyre PM; Steis RG; Longo DL; Urba WJ
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):181-90. PubMed ID: 8471592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-related immunologic effects of levamisole in patients with cancer.
    Janik J; Kopp WC; Smith JW; Longo DL; Alvord WG; Sharfman WH; Fenton RG; Sznol M; Steis RG; Creekmore SP
    J Clin Oncol; 1993 Jan; 11(1):125-35. PubMed ID: 8418223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting effects of interferon-gamma and interleukin-4 on neopterin generation from human adherent monocytes.
    Moutabarrik A; Takahara S; Namiki M; Kameoka H; Seguchi T; Yokokawa K; Takano Y; Sonoda T; Ishibashi M; Zaid D
    Lymphokine Cytokine Res; 1992 Dec; 11(6):327-30. PubMed ID: 1477185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-1 and tumor necrosis factor-alpha each up-regulate both the expression of IFN-gamma receptors and enhance IFN-gamma-induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1).
    Krakauer T; Oppenheim JJ
    J Immunol; 1993 Feb; 150(4):1205-11. PubMed ID: 8432976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of tumour necrosis factor-alpha on the expression of Fc IgG and IgA receptors, and other markers by cultured human blood monocytes and U937 cells.
    Gessl A; Willheim M; Spittler A; Agis H; Krugluger W; Boltz-Nitulescu G
    Scand J Immunol; 1994 Feb; 39(2):151-6. PubMed ID: 8296157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.
    Smith JW; Urba WJ; Clark JW; Longo DL; Farrell M; Creekmore SP; Conlon KC; Jaffe H; Steis RG
    J Immunother (1991); 1991 Oct; 10(5):355-62. PubMed ID: 1790143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.
    Paulnock DM; Havlin KA; Storer BM; Spear GT; Sielaff KM; Borden EC
    J Interferon Res; 1989 Aug; 9(4):457-73. PubMed ID: 2502586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS).
    Troppmair J; Nachbaur K; Herold M; Aulitzky W; Tilg H; Gastl G; Bieling P; Kotlan B; Flener R; Mull B
    Clin Exp Immunol; 1988 Dec; 74(3):392-7. PubMed ID: 3148378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neopterin release from human endothelial cells is triggered by interferon-gamma.
    Andert SE; Griesmacher A; Zuckermann A; Müller MM
    Clin Exp Immunol; 1992 Jun; 88(3):555-8. PubMed ID: 1606740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.